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Abstract
Introduction: The purpose of this study was to investigate whether single-voxel (SV) proton magnetic resonance 
spectroscopy (MRS), diffusion-weighted imaging (DWI), and diffusion tensor imaging (DTI) detected differences 
between fibromyalgia (FM) patients and healthy controls. We also searched for correlations between neuroimaging 
abnormalities and neuropsychological variables.
Methods: Ten patients with FM and 10 gender- and age-matched control subjects were studied. A neuropsychological 
examination, DWI, DTI, and proton MRS were performed on the brain areas known to be associated with pain 
processing.
Results: Compared with healthy controls, FM patients had significantly higher levels of glutamate + glutamine (Glx) 
(mean ± SD, 10.71 ± 0.50 arbitrary institutional units versus 9.89 ± 1.04; P = 0.049) and higher glutamate + glutamine/
creatine (Glx/Cr) ratios (1.90 ± 0.12 versus 1.72 ± 0.23; P = 0.034) in the posterior gyrus. Myoinositol (Ins) levels of the 
right and left hippocampi were significantly lower in FM patients (4.49 ± 0.74 versus 5.17 ± 0.62; P = 0.008 and 4.91 ± 
0.85 versus 6.09 ± 0.78; P = 0.004, respectively). In FM patients, decreased myoinositol/creatine (Ins/Cr) ratios were 
found in the left sensorimotor area (P = 0.05) and the left hippocampus (P = 0.002) and lower levels of choline (P = 
0.019) and N-acetyl aspartate + N-acetyl aspartyl glutamate (NAA + NAG) (P = 0.034) in the left hippocampus. 
Significant correlations between depression, pain, and global function and the posterior gyrus Glx levels and Glx/Cr 
ratios were observed.
Conclusions: Glx within the posterior gyrus could be a pathologic factor in FM. Hippocampal dysfunction may be 
partially responsible for the depressive symptoms of FM. Additional studies with larger samples are required to confirm 
these preliminary data.
Introduction
Fibromyalgia (FM) is a prevalent and disabling disorder
characterized by a history of widespread pain for at least
3 months and patient-reported tenderness in at least 11
of 18 defined tender points on digital palpation with
about 4 kg per unit area of force [1]. With an estimated
lifetime prevalence of approximately 2% in a community
sample, FM accounts for 15% of outpatient rheumatology
visits and 5% of primary care visits [2]. The prognosis for
symptomatic recovery is generally poor [3]. No clear con-
sensus exists on the treatment of choice, and FM remains
relatively refractory to treatment [4].
The use of neuroimaging techniques for the study of
FM has increased in recent years [5]. Some of the differ-
ent neuroimaging methods used in this condition have
been multiple positron-emission tomography (PET) [6],
single-photon emission computed tomography (SPECT)
[7], functional magnetic resonance imaging [8,9], and dif-
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Page 2 of 12fusion-tensor and volumetric imaging [10]. DTI has been
effectively used for the investigation of pain. Some studies
with this technique suggest that some brain structures are
activated during painful conditions in healthy controls
[11]. More recently, a growing body of literature suggests
that glutamate (Glu), an excitatory neurotransmitter
within the central nervous system, may play a role in FM
pathology [12,13].
MRS provides a noninvasive method for characterizing
chemical and cellular features in vivo. MRS can be used to
measure the chemical composition of tissues, character-
ize certain tissue metabolic processes, and identify unan-
ticipated chemical or metabolic relations with disease. In
brain tissue, the concentrations and mobility of MRS-vis-
ible low-molecular-weight chemicals are measured as
spectral peaks and can be used to detect abnormalities in
brain regions that seem normal in magnetic resonance
imaging (MRI) and to elucidate the pathology underlying
MRI-visible abnormalities [14].
Diffusion-weighted imaging (DWI) is a sensitive tool
that allows physiological alterations in water diffusion to
be quantified. The apparent diffusion coefficient (ADC)
is a measure of the magnitude of diffusion of the water
molecules and reduced restriction, generally as the result
of expansions of the extracellular space. These expansions
could be produced by neural loss, glial loss, astrocytosis,
or the presence of any other pathologic changes [15].
White matter composes half of the human brain and
consists of bundles of myelinated axons connecting neu-
rons in different brain regions. Gray matter is composed
of neuronal cell bodies and dendrites concentrated in the
outer layers of the cortex. Microstructural changes in
white matter can be revealed by specialized MRI brain-
imaging techniques such as diffusion tensor imaging
(DTI). DWI and DTI provide evidence that subtle abnor-
malities exist in neuronal function in pain-processing
regions of the brain, in particular, in fibromyalgia, sug-
gesting that thalami play a significant role in the pain pro-
cessing in FM [16].
DTI analyzes the fractional anisotropy (FA) of proton
diffusion in tissue, which is more restricted in white mat-
ter than in gray matter. FA is a measure of the directional-
ity of diffusion. In a healthy brain, the movement of water
is expected to be anisotropic, preferentially flowing in
one direction, such as along white-matter tracts, without
much movement into the space outside the axon. Anisot-
ropy increases with increased myelination, fiber diameter,
and axon compaction. These data can be used to calcu-
late the probable anatomy of white-matter fiber bundles
in living brains, a process called tractography. The fiber
orientation is calculated from the eigenvectors that define
proton diffusion in three dimensions in each voxel. With
algorithms, the principal eigenvalue vector is connected
to the next voxel to trace the fiber structure and orienta-
tion in white-matter tracts [15].
Nearly all published works have focused on the diag-
nostic ability of a single imaging technique rather than on
a comparison between several techniques. It is therefore
useful to define the relative utility of these MRI tech-
niques for distinguishing between FM and control
patients. The aim of this study was to investigate whether
single-voxel (SV) MRS, DWI, and DTI measurements can
detect cerebral abnormalities in fibromyalgia patients and
whether significant differences exist between these
patients and normal controls. In addition, we searched
for any possible correlations between neuroimaging
abnormalities and relevant clinical variables of FM.
Materials and methods
Method
This was a controlled, cross-sectional study.
Patients
The FM group was recruited from any of the primary
health care centers in the city of Zaragoza, Spain. The
patients were required to meet the following inclusion
criteria: be 18 to 65 years old and be able to understand
and read Spanish, fulfill the criteria for primary fibromy-
algia according to the American College of Rheumatology
[1], and have been diagnosed with fibromyalgia during
the last 2 years, and have discontinued pharmacologic
treatment 1 week before the study began or have modi-
fied the treatments so as not to affect brain imaging. All
the patients with FM included in the study took analge-
sics such as tramadol (10 of 10), pregabalin (eight of 10),
or paracetamol (five of 10). In addition, some of them
took the antidepressant duloxetine (six of 10) and benzo-
diazepines (three of 10). Treatment was discontinued 1
week before the study. During that week, patients were
allowed to take only occasional doses (maximum, one per
day) of analgesics such as tramadol or paracetamol, to
minimize the influence of medication on brain imaging.
Patients were excluded if they had Axis I psychiatric dis-
orders (depressive disorder, bipolar disorder, dementia,
schizophrenia, paranoid disorder, or alcohol and/or drug-
abuse disorders), were pregnant or lactating, and or if
they refused to participate.
The control group was recruited from among hospital
staff, with an adjustment for gender and age (± 3 years) to




Sociodemographic data Data on the gender, age, marital
status, education, and occupation of subjects were col-
lected.
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involves an exaggerated negative orientation toward nox-
ious stimuli. The PCS is a 13-item self-reported question-
naire whose validity and reliability were previously
reported [18]. We used the validated Spanish version of
this questionnaire [19].
Hospital Anxiety Depression Scale (HADS) This is a
self-reported scale designed to screen for the presence of
depression and anxiety disorders in medically ill patients.
It contains 14 items rated on 4-point Likert-type scales.
Two subscales assess depression and anxiety indepen-
dently (HADS-Dep and HADS-Anx, respectively) [20].
Patients with 14 or more points in the complete scale (or
more than 8 in either of the two subscales) were consid-
ered "probable cases" of anxiety or depression or both.
We used the validated Spanish version of this question-
naire [21].
Pain Visual Analogue Scale (PVAS) The PVAS was
designed to allow a thorough and understandable subjec-
tive assessment of pain. A Visual Analogue Scale is usu-
ally a 10-cm horizontal line, with perpendicular lines on
the edges, defined as the extreme limits of pain experi-
ence. Anchoring points at each edge are characterized by
verbal expressions such as 'No pain' (accompanied by the
number 0) at one edge and 'maximum pain ever experi-
enced' (accompanied by the number 100) at the other
edge. The adequate psychometric properties of PVAS
were demonstrated in previous studies [22]. We used the
validated Spanish version of this questionnaire.
Pain threshold assessed by sphygmomanometer It has
been demonstrated that the sphygmomanometer, a uni-
versally used clinical test, is helpful in the identification of
patients with FM [20]. It has been recommended that the
blood pressure cuff be inflated at an approximate rate of
10 mm Hg per second up to 180 mm Hg or to the point at
which pain is elicited. Healthy persons usually experience
pain when the blood pressure cuff is inflated to 160 mm
Hg or more; patients with FM, though, usually experience
pain at 100 to 110 mm Hg, or even with less pressure [23].
Mini-Mental State Exam (MMSE) This is a fully struc-
tured scale that consists of 30 points grouped into seven
categories: orientation to place, orientation to time, regis-
tration, attention and concentration, recall, language, and
visual construction. The psychometric properties of the
test were previously described. In nongeriatric popula-
tions (younger than 65 years), such as the sample in our
study, the threshold that suggests a 'probable case' of cog-
nitive disorder is less than 27 points [24]. We used the
validated Spanish version of this questionnaire [25].
Fibromyalgia Impact Questionnaire (FIQ) The FIQ is a
10-item self-reported questionnaire developed to mea-
sure the health status of FM patients [26]. The first item
focuses on the patient's ability to carry out muscular
activities. In the next two items, patients are asked to cir-
cle the number of days in the past week on which they felt
good and how often they missed work. Finally, the last
seven questions (job ability, pain, fatigue, morning tired-
ness, stiffness, anxiety, and depression) are measured
with a visual analogue scale (VAS). We used the validated
Spanish version of this questionnaire [27].
Neuroimaging techniques
Magnetic resonance imaging (MRI) Data were acquired
by using a 1.5-T Sigma HD clinical scanner (GE Health-
care Diagnostic Imaging, Milwaukee, WI, USA). All
images were acquired by using an eight-channel phased-
array head coil (NVHEAD A). For each subject, a three-
dimensional high-resolution (1-mm isotropic voxels)
structural magnetic resonance image was acquired by
using a T1-weighted volumetric spoiled gradient-recall
echo sequence (repetition time (RT) = 9.1 ms; echo time
(ET) = 1.7 ms; inversion time (IT) = 450 ms, 20-degree
flip angle, number of excitations = 1; matrix size = 256 ×
160; slice thickness = 1.5 mm; yielding 140 coronal slices
with an in-plane resolution of 1 × 1 mm).
Functional magnetic resonance imaging (fMRI) fMRI
acquisition consisted of a single-shot gradient-echo echo-
planar imaging (EPI) sequence, which was used to
acquire repeatedly a series of T2-weighted images (FOV =
24 cm; TE/TR/flip = 60/3,000 msec/90 degrees; slice
thickness/gap = 5/0 mm; matrix size = 64 × 64) at 25 slice
locations encompassing the motor cortex region. In total,
64 images were collected at each slice location, which
correspond to a series of four dummy acquisitions fol-
lowed by 6 times periods of 10 volumes each. Motor cor-
tex stimulation was alternated with rest periods, with
each period lasting 30 sec. During the task period, the
subjects were asked to perform a self-paced finger-thumb
opposition of the contralateral hand. These images were
subsequently processed off-line by using the commercial
clinical software FuncTool 3.1.23 (General Electric Medi-
cal System, Milwaukee, WI). Preprocessing of the func-
tional MR data included motion correction, slice-time
correction, and temporal drifting correction. The Student
t test was used with a confident level of 0.001 to identify
the statistically significant pixels. The co-registration of
the t-test maps with the anatomic image was performed
to obtain the anatomic localization of the functional foci.
Magnetic resonance spectroscopy (MRS) An axial T2-
weighted image was used to locate volumes of interest
(VOIs) (2 × 2 × 2 cm) in the left primary sensorimotor
area and both halves of the thalamus. A coronal T2-
weighted image in the plane that goes through inner
auditive conducts and brain peduncle was used to locate
volumes in both hippocampi, and a midsagittal T1-
weighted image was used to locate a voxel on the poste-
rior gyrus (Figure 1). A close negative correlation
between global measurement-scale scores and NAA lev-
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shown in cognitive impairment [28-30], and cognitive
dysfunction is a key symptom in FM.
1H-MRS was carried out by means of a short echo-time
(ET) of 35 msec and a repetition time (RT) of 2,000 msec
and 128 accumulations by using a single-voxel stimu-
lated-echo acquisition-mode localization sequence with a
spin-echo technique that uses selective excitation with
gradient spoiling for water suppression. The mode of
spectral acquisition was probe-p (PRESS technique).
Chemical concentrations can now be automatically
extracted from MR spectra by using sophisticated and
well-documented time-domain and spectral frequency-
fitting software packages such as LCModel (Stephen
Provencher, Oakville, Ontario, Canada), a user-indepen-
dent fitting routine based on a library of model spectra of
all individual metabolites [31]. Concentration values are
expressed as arbitrary institutional units and are not cor-
rected for contributions by CSF and a small reduction in
the numeric values by residual T1 and T2 relaxation
effects. The data evaluation comprised a correction of the
spectroscopic time-domain data for residual eddy-cur-
rent effects. Quantifiable chemicals by MRS included the
following: N-acetylaspartate (NAA; most often measured
as the total of NAA + N-acetylaspartyl glutamate [Glu]),
2.02 ppm; glutamine and glutamate (Glx), 2.1 to 2.55
ppm; total creatine (Cr; composed of creatine and phos-
phocreatine), 3.03 ppm; choline-containing compounds
(Cho), 3.23 ppm; and myoinositol (mI), 3.56 ppm (Figure
2). We also obtained the ratios of the peak amplitude of
the metabolites relative to creatine. The areas of explora-
tion were chosen on the basis of brain structures that are
activated during painful conditions in healthy controls,
the somatosensory cortices and the thalamus, and the
regions in the previously mentioned reports implicated in
cognitive impairment, the hippocampus and posterior
gyrus [32]. Before starting this study, we studied the test-
retest reliability of metabolite measurements in every
area in a sample of patients with other pathologies, with
two consecutive studies, without removing the patient
from the scanner. According to the resulting α coeffi-
cients, we must assume a mean random variation in the
posterior gyrus of around 8% for mI/Cr and of around
10% for NAA/Cr, Cho/Cr, and glutamate [33].
Diffusion tensor imaging (DTI) These images were
obtained by using a single-shot, spin-echo EPI technique
with a b-value of 1,000 s/mm2 for each of 25 diffusion-
encoding directions, ET = 94.5 ms, TR = 8,000 ms, matrix
= 128 × 128, field of view, 24 cm, 3-mm slice thickness
with no gaps, 25 slices, and a scan time of 3.44 min. The
diffusion MR data were analyzed by using the diffusion
tensor model. After a mathematical diagonalization pro-
cess, the eigenvectors and eigenvalues describing the ten-
sor ellipsoid were determined. Subsequently, two
standard diffusion indices were derived: the apparent dif-
fusion coefficient (ADC) and the fractional anisotropy
(FA) [13]. The ADC and FA maps were calculated off-line
with the Functool software 3.1.23 in the Advantage
Workstation 4.3 (General Electric Medical Systems, Mil-
waukee, WI) by the following procedure. Initially, images
were preprocessed to remove image-to-image misregis-
tration that arises from directional eddy currents during
echo-planar readout. Directional diffusion-weighted
images (DWIs) were spatially registered to the b ? 0
image, which was set to remove image shear, compres-
sion, and shift by an affine transform. ADC is considered
quantitative with normal brain values of ADC ? 0.7 × 10-3
mm2/sec, and FA is a dimensionless value between zero
(isotropic) and close to 1 (highly anisotropic environ-
ments).
Figure 1 Voxel placement in the different brain regions. The hip-
pocampus (a, b), thalamus (c, d), posterior gyrus (e), and left sensorim-
otor (f) (red) after functional magnetic resonance imaging during 
finger-tapping tasks.
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(ROIs) were placed at the following areas, most of them
known to be associated with pain processing: the lemnis-
cus medial, amygdala, periaqueductal gray, insular cortex,
orbitofrontal cortex, internal capsule, middle thalamus,
dorsolateral thalamus, corpus callosum, dorsolateral pre-
frontal cortex, gyrus cortex, parietal and frontal white
matter, and somatosensory cortex (Figure 3). The mean
ADC and FA in the different regions were compared
between the two groups.
The total scanning time for six MRS acquisitions
(30:20), a T1-weighted volumetric spoiled gradient-recall
echo sequence (5:39), T1- (1:39) and T2-weighted scans
(1:11), an fMRI run (3:12), and DWI (3:44) was 44:65.
Blood tests
Venous blood was drawn between 9:00 am and 11:30 am.
When the blood was extracted, it was placed into two
containers for separation:
Container (a): A container with only serum. This was
centrifuged and coagulated. In this sample, lactate dehy-
drogenase (LDH) and serotonin were studied.
Container (b): A container with blood. This was centri-
fuged, and an anticoagulant (EDTA tripotasic) was added.
This was frozen at -30°C Celsius until use. In this sample,
ammonia was studied.
Ammonia and LDH levels were measured with molecu-
lar absorption spectrometry, and serotonin was measured
with chromatography. The results were expressed as indi-
vidual patient levels and reference values, by using micro-
moles per liter and micrograms per deciliter (ammonia),
microKat per liter and Units per liter (LDH) and nano-
moles per liter and nanograms per milliliter (serotonin).
Statistical methods
To describe the quantitative variables, the means and
standard deviations were calculated. A nonparametric
Mann-Whitney U test was used to analyze possible dif-
ferences in brain metabolite levels between patients with
fibromyalgia and healthy controls. In addition, we used
the nonparametric Spearman's rho correlation in the FM
group to study the relation between brain metabolites for
which the levels were significantly different in FM
patients compared with those in healthy controls, and the
clinical variables were studied. To determine the statisti-
cal significance in psychological and blood tests between
the controls and patients with FM, a Mann-Whitney U
test was used. Statistical analyses were carried out by
using SPSS 15.0, and p values lower than 0.05 were con-
sidered statistically significant for all analyses.
Ethical aspects
Informed consent was obtained from the participants
before their inclusion in the study. The study protocol
was approved by the ethical review board of the regional
health authority.
Figure 2 Left hippocampus spectrum. A control patient (a) and a patient with fibromyalgia (FM) (b). For the patient with FM, a decrease in the myo-
inositol peak amplitude and in the relation to creatine was noted. The black line indicates the averaged spectrum; the red line indicates the LCModel 
fit. The residuals, calculated as a subtraction of the fit from the average spectrum, are plotted at the top.
a) b)
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Sociodemographic and psychological variables and pain 
measurements
Ten patients (eight women and two men) with FM and 10
gender- and sex-matched control subjects were studied.
The mean age of FM patients was 40.0 (SD = 6.2) years,
and the mean age in the control group was 37.8 (SD = 8.7)
years. As expected, no significant differences were found
in these two variables because of a matching process.
Neither group had any psychiatric disorder, as was con-
firmed by the SPPI psychiatric interview. In the control
group, rating scores in the psychopathology question-
naires were within the normal ranges.
In the FM group, the mean duration of the disorder was
1.6 (SD = 0.3) years. The psychological profile showed the
usual psychological characteristics of FM patients: high
scores in anxiety (mean, 6.2; SD, 2.8) and depression
(mean, 5.9; SD, 3.8) assessed with HADS; high scores on
the pain-catastrophizing scale (mean, 27.0; SD, 9.9) and
in pain assessed with PVAS (mean, 63.0; SD, 17.0); and a
low pain threshold in the sphygmomanometer test
(mean, 107.0; SD, 25.8). The MMSE scores suggested a
certain cognitive dysfunction in FM (mean, 30.6; SD, 3.3),
but it was not as severe as that found in patients with
dementia.
Blood test
The blood concentration of 5-hydroxytryptamine (sero-
tonin) decreased significantly in the FM group, with a
range from 21 to 229 nM (mean, 77.3). Two patients with
FM showed an increased level of lactate dehydrogenase
(mean, 85.2 nKat/L). Table 1 summarises psychological




The conventional MR images were normal with respect
to the brain parenchyma in all subjects.
DWI and DTI
With regard to diffusion-weighted images and diffusion-
tensor imaging, we did not detect significant differences
in any of the areas.
MRS
FM patients showed increased combined glutamine and
glutamate (that is, Glx) and decreased myoinositol levels.
Table 2 shows that individuals with FM displayed ele-
vated glutamate+glutamine (Glx) and an elevated Glx/Cr
ratio in the posterior gyrus (P = 0.049 and P = 0.034,
respectively) compared with healthy controls. Myoinosi-
tol (Ins) levels in the right and left hippocampi were sig-
nificantly lower in FM patients compared with controls
(P = 0.008 and P = 0.004, respectively). FM patients also
showed lower myoinositol/creatine (Ins/Cr) ratios in the
left sensorimotor area (P < 0.05) and the left hippocam-
pus (P = 0.002) compared with controls. An example of a
spectrum is given in Figure 2. Another statistically signif-
icant difference was observed for choline (P = 0.019) and
NAA+NAG (P = 0.034) in the left hippocampus, with lev-
els being lower in the patient group compared with con-
trols.
Regarding Glx and Glx/Cr in the posterior gyrus and
psychological variables, significant correlations between
depression, pain measured with a sphygmomanometer,
and global function measured with FIQ and the posterior
gyrus Glx and Glx/Cr levels were observed (Table 3). The
scatterplot of the correlations between brain metabolites
and psychological variables that are significantly different
between patients with FM and controls are shown in Fig-
ure 4. These data suggest that, regardless of whether an
Figure 3 Axial images showing the different locations of the 
equal-sized regions of interest (ROIs). The ROI placements for the 
periaqueductal gray and amygdale (a), the orbitofrontal cortex and in-
sular cortex (b), the internal capsule and ventral and dorsolateral thal-
amus (c), the gyrus cortex and corpus callosum (d), the frontal white 
matter, parietal white matter, and dorsolateral prefrontal cortex (e), 
and the sensorimotor area (f).
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als with higher levels of Glx and Glx/Cr also have
enhanced sensitivity to induced pressure pain.
Discussion
In this pilot study, we compared three different magnetic
resonance imaging (MRI) examination methods for the
diagnosis of fibromyalgia: magnetic resonance spectros-
copy, diffusion-weighted imaging, and diffusion-tensor
imaging. To our knowledge, this is the first controlled
study to compare these different neuroimaging examina-
tion methods directly in patients with fibromyalgia. The
main limitations of this study are the small sample size (n
= 10), as is usual in pilot studies, and the fact that this
exploratory study did not attempt to control for multiple
comparisons. Finally, the interpretation of significant dif-
ferences in the metabolite concentrations should be cau-
tious because spectroscopic voxels contain varying
mixtures of gray matter, white matter, and CSF.
Performance of different neuroimaging techniques for the 
diagnosis of FM
Previous studies with diffusion-tensor imaging in FM
patients showed alterations in the right thalamus and sig-
nificantly lower fractionated anisotropy compared with
controls. A negative correlation was seen between the FA
values in the right thalamus and clinical pain in the FM
group [16]. Other authors confirmed that DTI in the
brains of patients with FM appears to be more sensitive
than volumetric imaging of voxel-based morphometry
(VBM), and increased pain-intensity scores were corre-
lated with changes in DTI measurements in the right
superior frontal gyrus. Increased fatigue was correlated
with changes in the left superior frontal and left anterior
gyri, and self-perceived physical impairment was corre-
lated with changes in the left postcentral gyrus [10].
In our study, the DWI and DTI were not sensitive
enough to detect changes in fibromyalgia patients. This
may be explained because the intraparenchymal injection
of glutamate or other excitatory amino acids predomi-
nantly affects neuronal cell bodies and dendrites, whereas
axons and terminal boutons, originating from cell bodies
outside of the affected region, remain largely intact [34].
In addition, only one average was acquired for DWI; this
would be expected to have a rather low signal-to-noise
ratio, and therefore, negative findings have to be consid-
ered with caution.
Correlations between brain metabolites and pain and 
psychological variables
In our study, a significant correlation was noted in the
posterior gyrus between Glx levels and Glx/Cr ratios with
depression (higher levels of glutamate correlated with
higher depression scoring), pain measured with a sphyg-
momanometer (high levels of glutamate correlated with
lower sphygmomanometer pressure, which means more
proneness to experiencing pain), and global function
assessed with FIQ (higher levels of glutamate levels corre-
lated with worse global function). Because astrocytes par-
ticipate in the uptake, metabolism, and recycling of
glutamate, we hypothesize that an astrocytic deficit may
account for the alterations in glutamate/GABA neu-
rotransmission in depression. Factors such as stress,
excess glucocorticoids, altered gene expression of neu-
rotrophic factors and glial transporters, and changes in
extracellular levels of neurotransmitters released by neu-
rons may modify glial cell numbers and affect the neuro-
physiology of depression [35]. Other studies found that
the absolute concentrations of glutamate+glutamine
(Glx), glutamate (Glu), and creatine+phosphocreatine
(Cr) were significantly higher in adult bipolar patients in
all mood states compared with healthy controls [36].
Glutamate has been implicated as an important media-
tor in the neurotransmission, potentiation, and negative
effects associated with pain, and it has been related to
chronic pain sensitization [37]. Our data suggest that Glu
plays a role in this augmented pain processing in those
individuals who have elevated Glu levels. Because higher
Table 1: Psychological and blood-test variables in controls 







PVAS 16.50 ± 5.79 63.0 ± 17.02 < 0.001
Sphigmo 170.50 ± 7.24 107.0 ± 25.84 < 0.001
MMSE 34.90 ± 0.31 30.60 ± 3.37 < 0.001
Catastroph 4.90 ± 2.02 27.0 ± 9.98 < 0.001
FIQ 17.50 ± 4.85 70.20 ± 10.50 < 0.001
HADS-Anx 0.70 ± 0.67 7.40 ± 0.69 < 0.001
HADS-Dep 0.60 ± 0.51 6.90 ± 0.87 < 0.001
Blood-test variables
Serotonin 273.50 ± 10.42 297.56 ± 249.70 0.449
GDH 47.10 ± 2.23 48.33 ± 23.51 0.568
Ammonium 17.40 ± 1.34 28.32 ± 9.26 < 0.001
All calculations were performed by using the Mann-Whitney U test.
Catastroph, Pain catastrophization scale; FIQ, Fibromyalgia Impact 
Questionnaire; GDH, glutamate dehydrogenase; HADS-Anx, 
Hospital Anxiety Depression Scale, subscale anxiety; HADS-Dep, 
Hospital Anxiety Depression Scale, subscale depression; MMSE, Mini 
Mental State Examination; PVAS, Pain Visual Analogue Scale; 
Sphigmo, pain assessed by sphygmomanometer.
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is likely that Glu in the posterior cingulate is related to
pain processing. The elevated levels of Glu in the FM
group could raise the set point of baseline neural activity
in this region, which could result in augmented responses
to painful stimuli [38].
FM patients may have more Glu within their synaptic
vesicles, higher numbers or densities of glutamatergic
synapses, or even less uptake of Glu from the synaptic
cleft. Any of these changes would be consistent with the
hypothesis that augmentation of pain and sensory pro-
cessing is found in FM. FM may represent a condition in
which glutamatergic "hyperactivity" occurs within brain
regions devoted to processing and modulating pain. The
results suggested increased glutamatergic metabolism in
exacerbated chronic illness or as a medication effect.
An alternative hypothesis is that the increase of glu-
tamine in astrocytes could precipitate a cascade of meta-
bolic events that will ultimately result in neuronal
dysfunction [39]. One of the consequences of the
increased glutamine levels in astrocytes is cellular swell-
ing, which has been demonstrated in preparations of
astrocytes and in experimental models in rats [40]. The
findings of 1H-MR spectroscopy in humans are in accor-
dance with the development of astrocyte swelling. The
intraparenchymal injection of glutamate predominantly
affects neuronal cell bodies and dendrites [34]. Because
astrocytes participate in the uptake, metabolism, and
recycling of glutamate, we hypothesize that an astrocytic
deficit may account for the alterations in glutamate/
GABA neurotransmission in FM.
Differences in brain metabolites between patients with FM 
and controls
Glutamate+Glutamine
One of the principal findings in our study was the
increase in the combined glutamate+glutamine (Glx) lev-
els and glutamate+glutamine/creatine ratio (Glx/Cr) in
the posterior gyrus (Figure 3) in individuals with FM
compared with controls. Because higher Glx levels were
associated with lower pain thresholds, this suggests that
Glx in the posterior gyrus is related to pain processing.
The elevated levels of Glx in the FM group could raise the
set point of baseline neural activity in this region, which
could result in augmented responses to painful stimuli. It
has been demonstrated that painful stimuli elicit a
dynamic increase in glutamate in the anterior cortex [40].
Increases in glutamine levels also were seen, and these
levels correlated strongly with the subjective level of pain
experienced by participants [41]. Other studies have
shown an increase in glutamate and Glx in the right pos-
terior insula, which is associated with lower pressure-
pain thresholds [11,12].
Elevated glutamine and glutamate inside the astrocytes
leads to increased cellular osmolarity in the brain. Within
30 minutes of glutamate administration, electron micros-
copy reveals massive acute swelling of neuronal cell bod-
ies and dendrites. Consequently, water shifts from the
extracellular fluid space to the intracellular fluid space,
resulting in edema of the astrocytes [42]. Relevant clinical
manifestations are thought to be secondary to this edema
[39]. To compensate for the increased cellular osmolarity,
myoinositol shifts to the extracellular space, leading to
reduction in its concentration inside the astrocyte. In
consequence, glutamate+glutamine (Glx) is an excitatory
amino acid, and its increase indicates that the metabolic
function of patients with fibromyalgia differs from that of
controls. The elevation of Gln levels may result in perma-
nent cerebral damage.
Choline and NAA+NAAG
Our study confirms the reduction in choline and
NAA+NAAG in the left hippocampus (P = 0.019 and P =
0.034, respectively). In all the cases, brain metabolites
were lower in the patient group compared with the con-
trols. In this study, the mean choline levels obtained in
the left hippocampus were 1.47 ± 0.22 in fibromyalgia
patients compared with 1.72 ± 0.20 in controls.
Choline (Cho) participates in phospholipid metabolism
and osmotic regulation in glial cells. Increases in Cho res-
onance probably reflect increased membrane synthesis or
myelin destruction, whereas decreases in Cho are associ-
ated with osmolar changes in the brain or liver diseases
[43]. Disturbances of Cho and myoinositol have been
interpreted as a compensatory response to the increase in
intracellular osmolarity caused by the accumulation of
glutamine in astrocytes [42]. The reduction in the intrac-
ellular choline (Cho) levels is also a likely mechanism to
compensate for hyperosmolarity [36]. Low choline levels
have been observed in hepatic encephalopathy [44] in
stroke and HIV patients. Cho/Cr variability in the right
dorsolateral prefrontal cortex (DLPFC) was significantly
different between the FM and control groups.
The evoked-pain threshold correlated significantly with
the NAA/Cho ratios in the left insula and left basal gan-
glia [45]. Our findings are consistent with a recent H-
MRS study, which showed decreased NAA levels within
the hippocampus of individuals with FM [46]. In this
study, the mean NAA+NAAG levels obtained in the left
hippocampus were 6.27 ± 0.89 in fibromyalgia patients
compared with 7.05 ± 0.64 in the controls. In another
study, a reduction in the absolute concentration of NAA
of the right and left hippocampi was reported in a sample
of 15 patients with fibromyalgia [47].
The lower hippocampal NAA levels suggest neuronal
or axonal metabolic dysfunction, or some combination of
these processes. However, neuronal loss within the hip-
pocampus was not studied in our series, and this should
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within the hippocampus. Some studies found that the
persistence of elevated Ca2+ levels in hippocampal neu-
rons exposed to glutamate correlated with the extent of
neuronal death [48] and that a large increase in Ca2+ in
cultured hippocampal neurons after glutamate applica-
tion predicted cell death [49]. We suggest that hippocam-
pal dysfunction may be in part responsible for some of
the phenomena associated with FM. Blocking N-methyl-
D-aspartate (NMDA) receptors in the hippocampal for-
Table 2: Comparison of absolute and relative Cr metabolite levels between FM patients and healthy controls
Metabolite location Healthy group FM group P value
Posterior cingulate gyrus
Glx 9.89 ± 1.04 10.71 ± 0.50 0.049
Glx/Cr 1.72 ± 0.23 1.90 ± 0.12 0.034
Left hippocampus
Ins 6.09 ± 0.78 4.91 ± 0.85 0.004
Ins/Cr 1.22 ± 0.07 1.09 ± 0.08 0.002
Cho 1.72 ± 0.20 1.47 ± 0.22 0.019
NAA+NAAG 7.05 ± 0.64 6.27 ± 0.89 0.034
Right hippocampus
Ins 5.17 ± 0.62 4.49 ± 0.74 0.008
Sensorimotor cortex
Ins/Cr 0.84 ± 0.07 0.76 ± 0.09 0.05
Values are expressed as the mean ± SD (in arbitrary institutional units).
Cho, choline; Cr, creatine; FM, fibromyalgia; Glx, glutamate+glutamine; Glx/Cr, glutamate+glutamine/creatine ratio; Ins, myoinositol; Ins/Cr, 
myoinositol/creatine ratio; NAA+NAAG, N-acetylaspartate + N-acetylaspartyl glutamate.
Table 3: Correlations between brain metabolites that show significant differences between both groups and 
psychological variables
Metabolite HADS-anx HADS-dep PVAS Sphigm MMSE Catastroph FIQ
Posterior cingulate gyrus Glx
(Coefficient) 0.43 0.44 0.37 -0.45 0.39 0.40 0.45
(P value) 0.057 0.047a 0.107 -0.047a 0.089 0.081 0.043a
Posterior cingulate gyrus Glx/Cr ratio
(Coefficient) 0.42 0.47 0.39 -0.50 0.36 0.40 0.55
(P value) 0.062 0.034a 0.08 -0.024a 0.117 0.077 0.011a
aP < 0.05.
Catastroph, Pain catastrophization scale; FIQ, Fibromyalgia Impact Questionnaire; Glx, glutamate+glutamine; Glx/Cr, glutamate+glutamine/
creatine ratio; HADS-Anx, Hospital Anxiety Depression Scale, subscale anxiety; HADS-Dep, Hospital Anxiety Depression Scale, subscale 
depression; MMSE, Mini Mental State Examination; PVAS, Pain Visual Analogue Scale; Sphigm, pain threshold assessed by 
sphygmomanometer (the pressure that is needed to evoke pain).
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ports the hypothesis that the hippocampal formation is
involved in the pain-related neural processing and
expression of pain-related behaviors [50].
Myoinositol
Finally, our study confirmed the reduction in myoinositol
levels in both hippocampi and the reduction in myoinosi-
tol/Cr ratios in the left hippocampus and sensorimotor
area. In all the cases, brain metabolites were lower in the
patient group compared with the controls. Changes in
these brain metabolites were previously described in
patients with bipolar disorder [51]. Research suggests
that lithium functions primarily by decreasing myoinosi-
tol concentrations in bipolar patients [52]. In addition,
patients with clinical depression generally have decreased
levels of inositol in their cerebrospinal fluid [53]. A fre-
quent association of FM with affective disorders has been
described [54].
Conclusions
According to our results, the only brain metabolite that
showed a significant correlation with pain and psycholog-
ical variables was glutamate + glutamine (Glx), which
correlates with depression, pain, and global function.
Overall, we found that Glx within the posterior gyrus was
a potential pathologic factor in FM, and we speculate that
myoinositol might, through its conversion to glucuronic
acid, be consumed in the protective detoxification reac-
tions of the brain. We suggest that hippocampal dysfunc-
tion may be in part responsible for some of the
phenomena associated with depression in FM patients.
New studies with larger samples are necessary to confirm
these preliminary data. Our findings may indicate ways to
find new therapeutic strategies for the treatment of
patients with this puzzling syndrome.
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